AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca could upgrade expectations after setting out bold growth plans
AstraZeneca PLC (LSE:AZN) releases its quarterly results next Thursday in the wake of an Investor Day at which outlined its bold plan to almost double its turnover to $80 billion by the end of the decade bolstered by a strong pipeline of new drugs, particularly in oncology. Against this backdrop, and a strong financial performance in the first quarter, analysts are now asking whether the Anglo-Swedish drugs giant will upgrade its already bullish financial forecasts for 2024.
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca has a 'catalyst-rich' period ahead
British pharmaceuticals megacap AstraZeneca PLC (LSE:AZN) shares surged nearly a percentage point higher on Friday, reflecting what broker Shroe Capital Markets sees as a “catalyst-rich period ahead”. “AstraZeneca outlined its ‘bold ambition' to deliver $80bn revenue by 2030 during its recent Investor Day, something we believe looks readily deliverable given the depth, breadth and momentum of the R&D pipeline, particularly in oncology,” said Shore Cap.
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.
Aptamer Group up 12% on AstraZeneca collaboration
Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a type of genetic material used in therapies. Optimers are synthetic molecules designed to bind specifically to target cells, enhancing the delivery and effectiveness of treatments.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks.
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
